| First Author | Volpatti JR | Year | 2020 |
| Journal | Elife | Volume | 9 |
| PubMed ID | 32223895 | Mgi Jnum | J:291691 |
| Mgi Id | MGI:6443121 | Doi | 10.7554/eLife.52946 |
| Citation | Volpatti JR, et al. (2020) Identification of drug modifiers for RYR1-related myopathy using a multi-species discovery pipeline. Elife 9:e52946 |
| abstractText | Ryanodine receptor type I-related myopathies (RYR1-RMs) are a common group of childhood muscle diseases associated with severe disabilities and early mortality for which there are no available treatments. The goal of this study is to identify new therapeutic targets for RYR1-RMs. To accomplish this, we developed a discovery pipeline using nematode, zebrafish, and mammalian cell models. We first performed large-scale drug screens in C. elegans which uncovered 74 hits. Targeted testing in zebrafish yielded positive results for two p38 inhibitors. Using mouse myotubes, we found that either pharmacological inhibition or siRNA silencing of p38 impaired caffeine-induced Ca(2+) release from wild type cells while promoting intracellular Ca(2+) release in Ryr1 knockout cells. Lastly, we demonstrated that p38 inhibition blunts the aberrant temperature-dependent increase in resting Ca(2+) in myotubes from an RYR1-RM mouse model. This unique platform for RYR1-RM therapy development is potentially applicable to a broad range of neuromuscular disorders. |
